NCT01892137View on ClinicalTrials.gov

Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%

PHASE1CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

May 31, 2014

Conditions
Actinic Keratosis
Interventions
DRUG

Ingenol mebutate gel 0.05%

Once daily for 2 consecutive days

Trial Locations (10)

2060

Melanoma Institute Australia, North Sydney

2217

Southderm Pty Ltd, Kogarah

4152

South East Dermatology Centre, Carina Heights

4217

The Skin Centre, Benowa

6008

St John of God Dermatology, Subiaco

6100

Burswood Dermatology, Victoria Park

10117

Collegium Medicum Berlin GmbH, Berlin

42275

Medizinisches Zentrum Bonn Friedensplatz, Bonn

70499

Hautarztpraxis Prof. Dr. med. C. Termeer, Stuttgart

86179

Klinik für Dermatologie & Allergologie Klinikum Augsburg Süd, Augsburg

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY

NCT01892137 - Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05% | Biotech Hunter | Biotech Hunter